Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -41.02% is in line with its 5-year average of -44.23%, around the middle of its 5-year range (-77.12%–-20.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.33% above its 12-month average of -53.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -41.02%.
RETURN ON EQUITY (ROE)
-41.02%
RETURN ON EQUITY (ROE) AVG TTM
-53.49%
RETURN ON EQUITY (ROE) AVG 3Y
-52.40%
RETURN ON EQUITY (ROE) AVG 5Y
-44.23%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+23.33%
CURRENT VS 3Y AVG
+21.73%
CURRENT VS 5Y AVG
+7.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.44%
median of 550 covered companies
CURRENT VS SECTOR MEDIAN
-4.01%
vs the sector median at left
C4 Therapeutics, Inc.
Market Cap
$324.51M
Return on Equity (ROE)
-41.02%
TTM Avg
-53.49%
3Y Avg
-52.40%
5Y Avg
-44.23%
Market Cap
$324.38M
Return on Equity (ROE)
-86.10%
TTM Avg
-112.93%
3Y Avg
-76.30%
5Y Avg
-62.48%
Market Cap
$318.27M
Return on Equity (ROE)
-226.56%
TTM Avg
-87.78%
3Y Avg
-55.09%
5Y Avg
-55.09%
Market Cap
$331.54M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$335.22M
Return on Equity (ROE)
N/A
TTM Avg
34.79%
3Y Avg
145.50%
5Y Avg
100.23%
Market Cap
$308.22M
Return on Equity (ROE)
N/A
TTM Avg
30.84%
3Y Avg
30.84%
5Y Avg
30.84%
Market Cap
$345.41M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$301.25M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$352.14M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | $324.51M | -41.02% | -53.49% | -52.40% | -44.23% |
| Cabaletta Bio, Inc. (CABA)vs › | $324.38M | -86.10% | -112.93% | -76.30% | -62.48% |
| CapsoVision, Inc. (CV)vs › | $318.27M | -226.56% | -87.78% | -55.09% | -55.09% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $331.54M | -320.77% | -82.83% | -78.63% | -104.90% |
| Agenus Inc. (AGEN)vs › | $335.22M | N/A | 34.79% | 145.50% | 100.23% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $308.22M | N/A | 30.84% | 30.84% | 30.84% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $345.41M | -26.14% | -53.80% | -12.25% | 19.21% |
| Benitec Biopharma Inc. (BNTC)vs › | $301.25M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $352.14M | -62.56% | -108.31% | -79.06% | -57.33% |
| Opus Genetics, Inc. (IRD)vs › | $353.38M | N/A | -589.37% | -290.01% | -205.39% |
ROE
-41.0%
ROA
-28.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -41.02% |
| 2026-03-31 | -44.31% |
| 2025-12-31 | -40.92% |
| 2025-09-30 | -77.12% |
| 2025-06-30 | -64.10% |
| 2025-03-31 | -52.92% |
| 2024-12-31 | -48.76% |
| 2024-09-30 | -43.48% |
| 2024-06-30 | -43.66% |
| 2024-03-31 | -48.81% |
| 2023-12-31 | -53.83% |
| 2023-09-30 | -62.46% |
| 2023-06-30 | -59.84% |
| 2023-03-31 | -50.04% |
| 2022-12-31 | -44.32% |
| 2022-09-30 | -33.52% |
| 2022-06-30 | -28.84% |
| 2022-03-31 | -25.94% |
| 2021-12-31 | -21.53% |
| 2021-09-30 | -22.58% |
| 2021-06-30 | -20.94% |
| 2021-03-31 | -28.59% |
| 2020-12-31 | -23.62% |
| 2020-06-30 | -34.59% |
